Individual
DC projects
Research project
Novel preclinically-validated GATA3 inhibitor/degrader as a therapy for T-cell Acute Lymphoblastic Leukemia
Rationale and Objectives
The main aim of this project is to design, develop and validate new therapies for the treatment of T-ALL that provide antileukemic effects through the inhibition or degradation of the transcription factor GATA3.
The specific objectives of this research program are:
- Designing chemotypes of GATA3 inhibitors and GATA3-PROTAC degraders/molecular glues by using ligand based virtual screening on MolPort database, fragment-based design and molecular docking.
- Evaluating the effects of GATA3 inhibitors and PROTAC degraders/molecular glues on leukemic cell lines in vitro.
- Validating the therapeutic effect of GATA3 inhibitors and PROTAC degraders/molecular glues in vivo.
Estimated gross salary
34,800€/year
This project may be adapted to the evolving needs of the host laboratory while remaining within hemato-oncology research. The DC will undertake one or more secondments with a total duration of at least three months and up to one year. These secondments may take place within or outside the DN, preferably in international and intersectoral settings.